[heavyweight] 2018 hisico: revenue goes up, 58 important drugs are under research, 5 are about to be approved, and heavyweight varieties compete for consistency evaluation

Recently, Hisense Pharmaceutical Group Co., Ltd (hereinafter referred to as "Hisense") released the semi annual annual company annual report In the first half of 2018, Hisense's total operating revenue reached 1190307663 yuan, a year-on-year increase of 42.04%; the net profit attributable to the shareholders of the listed company reached 145364033 yuan, a year-on-year increase of 6.92% 1 Overall situation: with better development, HISCO is a diversified enterprise integrating new drug research and development, production and manufacturing, and sales in 2018 or reaching a new level of revenue In the pharmaceutical enterprises, it has a certain R & D strength, especially in the market share of parenteral nutrition segment ranked first, and it is a more famous liver disease drug manufacturer in China According to its annual development, from 2013 to 2017, hisic's development data (as shown in Figure 1), we can see that the company's revenue is growing in a straight line According to the data comparison (compared with figure 2), from 2013 to 2018, the semi-annual data trend of Hisilicon can be seen to be consistent with the annual trend, and it can be predicted that if it keeps stable development, the operating revenue of Hisilicon in 2018 will peak again Figure 1 annual overall development trend of Hisense Figure 2 annual overall development trend of Hisense In addition, according to its semi annual development trend, Hisense's investment in drug R & D and sales is also increasing year by year to ensure its strength in drug supply and market share In particular, the increase of sales expenses in recent two years is relatively large, which is related to the marketing reform of enterprises In the first half of 2018, HISCO completed the adjustment of new marketing mode, from the original agency system to the mixed and diversified marketing mode, established and completed the basic medical business department, completed the layout of 11 provinces and regions, and locked 500 terminals And this marketing reform has also promoted the apparent volume of some new products I believe that in the future, it will contribute more revenue to the enterprise 2、 Marketing situation: injection is the main force, and the revenue of other products is growing At present, many products of CISCO are relatively mature, and have a considerable market share Product marketing analysis shows that the main product of CISCO is injection, which brings the highest gross profit margin According to the comparison of data in 18 and 17 years, we can see that because the injection Market model is more strictly regulated, the proportion of Hisense's profitable products has also changed, the operating revenue of injection products is significantly reduced, and the revenue of other products is growing Figure 3: product marketing analysis 3 Core competition: dominated by new drugs, 58 important projects under research, 2 heavyweight drugs competing for conformity evaluation The core competitiveness of HISCO depends on the R & D layout of the enterprise and a number of excellent market-oriented products, such as polyene phosphatidylcholine injection, fat soluble vitamin series for injection, dorasetron mesylate injection, namefen hydrochloride injection, cefoperazone sodium tazobactam sodium for injection, methylprednisolone sodium succinate for injection, entecavir capsule, etc In addition, there are many products under research, and the consistency evaluation work is also actively carried out 01 declaration layout of new drugs according to the data of drug intelligence, hisic has applied for 219 drugs in CDE, mainly new drugs, accounting for 47.59%, followed by generic drugs, which shows that the company attaches great importance to the research and development of new drugs Fig 4 during the report period of pharmaceutical application type 02, there are 58 varieties, 7 innovative drugs, 48 generic drugs, 2 biological drugs, 1 special medical food in Hisilicon in the R & D stage, involving many fields, and the product line is very rich The progress of the main research projects is as follows: Fig 5 consistency evaluation of key research projects 03 At present, hispec has two products in the application for conformity evaluation, namely entecavir capsule and flupentixicine tablets Fig 6 consistency evaluation of hysico entecavir is the first-line drug for hepatitis B at present, 7 enterprises have applied for the consistency evaluation At present, entecavir dispersible tablets of Zhengda Tianqing and Jiangxi Qingfeng entecavir dispersible tablets and capsules have passed the consistency evaluation, while the progress of other application capsules is shown in Fig 7 Figure 7 the consistency evaluation progress of entecavir capsule flupentixomil tablets is used for depression In 2017, the market share of flupentixomil tablets was about 882 million yuan At present, Denmark Lingbei Pharmaceutical Co., Ltd and Hainan Huineng Pharmaceutical Co., Ltd are also applying for conformity evaluation Haisi subject has been applied for promotion, while Denmark Lingbei has completed be Fig 8 evaluation progress of consistency of flupentixicine tablets 04 among the products that are expected to be approved by HISCO in 2018, there are the following products that are likely to be approved for market in the second half of 2018, among which, carbufungin acetate for injection and levocarnitine chloroacetyl tablets are worth waiting for Kapofungin acetate is a semi synthetic β - 1,3-glucan synthesis inhibitor freeze-dried powder for intravenous injection developed and listed by Merck & Co it is the first listed echinocandin antifungal agent and has been widely sold in the world It is reported that the net market of kapofen in China is over 1 billion yuan At present, only Jiangsu Hengrui won the first imitated listing in 2017, and Hisilicon, if approved in 2018, will split this large market share The first indication of Levocarnitine in the world was depression, but later clinical trials found that it had better effect on Alzheimer's disease By the end of 2013, the main indications of the world's listed oral preparation of levocarnitine are primary and secondary neurodegenerative diseases caused by Alzheimer's disease, vascular dementia, Down's syndrome, or cerebrovascular diseases; in addition, diabetic neuropathy (diabetic neuropathic pain), chemotherapy-induced peripheral neuropathy Indication of change At present, there are many domestic approvals on Levocarnitine in China, but the tablet approval has not yet been obtained, and only hisilic reports the production application according to the new drug category 3.1 If it is approved, it may change the market situation At present, HISCO's competitiveness in the industry has not been significantly highlighted, but from the market situation of its existing products, the layout of products under research, the continuous innovation of marketing mode and the overall development situation, it is not difficult to see that the enterprise is slowly immersed in various practical situations of the industry like a trickle, which is a force that can not be ignored in the rising enterprises.